FDA Proposes Adding Constituents to Tobacco HPHC List

Legal Status This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.

The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to About the Federal Register on NARA's archives.gov.

The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.

Legal Status

Notice

Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List Additions and Request for Comments

A Notice by the Food and Drug Administration on 04/23/2026

• 1.

1.
This document has a comment period that ends in 33 days.
(05/26/2026)

Thank you for taking the time to create a comment. Your input is important.

Once you have filled in the required fields below you can preview and/or submit your comment to the Health and Human Services Department for review. All comments are considered public and will be posted online once the Health and Human Services Department has reviewed them.

You can view or you may also comment via Regulations.gov at /documents/2026/04/23/2026-07910/harmful-and-potentially-harmful-constituents-in-tobacco-products-and-tobacco-smoke-established-list.

It appears that you have attempted to comment on this document before
so we've restored your progress.
.
1.
2. Comment * What is your comment about? Upload File(s) Note: You can attach your comment as a file and/or attach supporting
documents to your comment. Attachment Requirements.

Email this will NOT be posted on regulations.gov

Opt to receive email confirmation of submission and tracking number? Tell us about yourself! I am... * An Individual An Organization Anonymous First Name * Last Name * City Region State Alabama Alaska American Samoa Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Guam Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virgin Islands Virginia Washington West Virginia Wisconsin Wyoming Zip Country Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Côte d'Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Macedonia, the Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestine, State of Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Phone Organization Type * Company Organization Federal State Local Tribal Regional Foreign U.S. House of Representatives U.S. Senate Organization Name * You are filing a document into an official docket. Any personal
information included in your comment text and/or uploaded
attachment(s) may be publicly viewable on the web. I read and understand the statement above.

2. Please review the Regulations.gov privacy notice and user notice.
3. Document Details Published Content - Document Details Agencies Department of Health and Human Services Food and Drug Administration Agency/Docket Number Docket No. FDA-2026-N-2642 Document Citation 91 FR 21824 Document Number 2026-07910 Document Type Notice Pages 21824-21829 (6 pages) Publication Date 04/23/2026 Published Content - Document Details

• PDF Official Content
  • View printed version (PDF) Official Content
• Document Details Published Content - Document Details Agencies Department of Health and Human Services Food and Drug Administration Agency/Docket Number Docket No. FDA-2026-N-2642 Document Citation 91 FR 21824 Document Number 2026-07910 Document Type Notice Pages 21824-21829 (6 pages) Publication Date 04/23/2026 Published Content - Document Details
• Document Dates Published Content - Document Dates Comments Close 05/26/2026 Dates Text Either electronic or written comments on the notice must be submitted by May 26, 2026. Published Content - Document Dates

• Table of Contents Enhanced Content - Table of Contents This table of contents is a navigational tool, processed from the
  headings within the legal text of Federal Register documents.
  This repetition of headings to form internal navigation links
  has no substantive legal effect.

  -

  -

  -

  -

  -

  -

  Enhanced Content - Table of Contents

• Public Comments Enhanced Content - Public Comments Comments are being accepted - .

Enhanced Content - Public Comments
- Regulations.gov Data Enhanced Content - Regulations.gov Data Additional information is not currently available for this document.

Enhanced Content - Regulations.gov Data

- Sharing Enhanced Content - Sharing Shorter Document URL https://www.federalregister.gov/d/2026-07910 Email Email this document to a friend Enhanced Content - Sharing

• Print Enhanced Content - Print
  • Enhanced Content - Print
• Other Formats Enhanced Content - Other Formats This document is also available in the following formats:

JSON Normalized attributes and metadata XML Original full text XML MODS Government Publishing Office metadata More information and documentation can be found in our developer tools pages.

Enhanced Content - Other Formats
- Public Inspection Public Inspection This PDF is FR Doc. 2026-07910 as it appeared on Public Inspection on
04/22/2026 at 8:45 am.

It was viewed
133
times while on Public Inspection.

If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507. Learn more here.

Public Inspection
Published Document: 2026-07910 (91 FR 21824) This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings Document headings vary by document type but may contain
the following:

1. the agency or agencies that issued and signed a document
2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
3. the agency docket number / agency internal file number
4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details.

Department of Health and Human Services

Food and Drug Administration

1. [Docket No. FDA-2026-N-2642]

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice; established list additions and request for comments.

SUMMARY:

The Food and Drug Administration (FDA, the Agency, or we) is adding constituents to the list of harmful and potentially harmful constituents (HPHCs) in tobacco products and tobacco smoke (the established HPHC list) as required by the Federal Food, Drug, and Cosmetic Act (the FD&C Act).

DATES:

Either electronic or written comments on the notice must be submitted by May 26, 2026.

ADDRESSES:

You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until ( printed page 21825) 11:59 p.m. Eastern Time at the end of May 26, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

• Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”
  Instructions: All submissions received must include the Docket No. FDA-2026-N-2642 for “Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List Additions and Request for Comments.” Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/​content/​pkg/​FR-2015-09-18/​pdf/​2015-23389.pdf.
  Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT:

Anna Julia Adams or Matthew Brenner, Center for Tobacco Products, Food and Drug Administration, Document Control Center, Bldg. 71, Rm. G335, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002; 1-877-287-1373, CTPRegulations@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Introduction

The Family Smoking Prevention and Tobacco Control Act (Pub. L. 111-31), enacted on June 22, 2009, amended the FD&C Act by, among other things, adding a new chapter (chapter IX) granting FDA the authority to regulate the manufacture, marketing, and distribution of tobacco products to protect the public health. Cigarettes, cigarette tobacco, roll-your-own (RYO) tobacco, and smokeless tobacco were immediately subject to chapter IX.

For other types of tobacco products, the statute authorizes FDA to issue regulations “deeming” them to be subject to chapter IX. FDA published a final rule on May 10, 2016, deeming all products that meet the statutory definition of “tobacco product” set forth in section 201(rr) of the FD&C Act (21 U.S.C. 321(rr)), including components and parts, but excluding accessories of deemed products, to be subject to chapter IX of the FD&C Act. ]

Section 904(e) of the FD&C Act (21 U.S.C. 387d(e)) requires FDA to establish, and periodically revise as appropriate, “a list of harmful and potentially harmful constituents, including smoke constituents, to health in each tobacco product by brand and by quantity in each brand and subbrand.”

In 2011, FDA provided guidance that discussed the meaning of “harmful and potentially harmful constituent” in the context of the HPHC list requirement (76 FR 5387, January 31, 2011). ] In 2012, after considering comments solicited from the public, as well as scientific and other information, FDA developed a list of 93 constituents in tobacco products and tobacco smoke that are believed to be harmful or potentially harmful to health (the HPHC established list). ]

In August 2016, FDA extended its authority under the Deeming Rule to all products, including components and parts (but excluding accessories of deemed products) that met the statutory definition of tobacco product, including electronic nicotine delivery systems (ENDS). Therefore, consistent with section 904(e) of the FD&C Act, the Agency considered revising the HPHC established list to reflect the current range of tobacco products now subject to the Agency's tobacco product ( printed page 21826) authorities as well as the Agency's growing scientific expertise with respect to all tobacco products. In 2019, the Agency requested comments on whether 19 additional constituents should be added to the HPHC established list. The Agency has considered comments solicited from the public, as well as scientific and other information, and has added tobacco product constituents to the established HPHC list that FDA currently believes are harmful or potentially harmful to health based on scientific evidence. FDA is adding 18 new constituents to the established list consistent with the requirement in section 904(e) of the FD&C Act to periodically revise, as appropriate, the established HPHC list (Table 1). In this document, we are also finalizing the addition of a new criterion for whether a constituent should be added to the list and seeking comments on the proposed addition of three new constituents to the list.

II. Background

FDA first established the HPHC list on April 3, 2012 (77 FR 20034) (the April 2012 notice). ] The list currently contains 93 HPHCs. The April 2012 notice describes the history of the HPHC established list, and for additional background, we refer readers to that notice and the notice FDA published in the Federal Register on August 12, 2011 (76 FR 50226) (the August 2011 notice), in which we solicited public comment, including scientific and other information, concerning the HPHCs in tobacco products and tobacco smoke, such as constituents that should be included on the HPHC established list, and the criteria used in determining whether a constituent is harmful or potentially harmful such that it should be included on the HPHC list. ]

Further, on August 5, 2019 (84 FR 38032) (the August 2019 notice), FDA published a request for comments on 19 additional constituents proposed to be added to the established list to reflect the current range of tobacco products subject to the Agency's tobacco product authorities as well as the Agency's growing scientific expertise with respect to all tobacco products. The August 2019 notice mentions FDA's application of existing criteria to deemed tobacco products to propose the addition of glycidol and ethylene glycol. Glycidol is a thermal byproduct of glycerol and a common component in e-liquids. Ethylene glycol, which has also been identified in e-liquids, adversely affects reproduction and development. The notice also stated that FDA would tentatively apply one additional criterion regarding whether a constituent should be included on the HPHC list: constituents identified by the National Institute for Occupational Safety and Health (NIOSH) as having adverse respiratory effects. The notice also proposed diethylene glycol (DEG) be added to the list due to it being a potential contaminant in either glycerol or propylene glycol. If ingested, DEG can cause kidney failure, neurological damage, and death.

When determining whether a constituent should be included on the established HPHC list, FDA considers whether there is evidence that the constituent meets established criteria, such as determinations from third-party scientific and public health organizations like NIOSH, the Environmental Protection Agency (EPA) or the Agency for Toxic Substances and Disease Registry (ATSDR). As part of the Centers for Disease Control and Prevention, NIOSH is the Federal agency responsible for conducting research and making science-based recommendations to prevent work-related illness and injuries, including those related to human health hazards and respiratory disease from inhalation exposures to toxicants. FDA has now finalized its previously tentative conclusion that constituents identified by NIOSH as respiratory toxicants will be an additional criterion that will be applied for determining whether a constituent should be included on the HPHC established list. The previously established criteria for determining whether a constituent should be included on the established HPHC list includes constituents identified by the EPA or ATSDR as having adverse respiratory or cardiac effects. Considering information from NIOSH in this regard is consistent with FDA's current practice of looking to other recognized, government experts such as EPA or ATSDR for their ability to identify constituents as having adverse respiratory or cardiac effects. As indicated by the original criteria (the April 2012 notice), FDA has previously considered this information from NIOSH when determining whether a constituent is harmful or potentially harmful by including constituents identified by NIOSH as a potential occupational carcinogen as a current criterion.

After review and consideration of the relevant comments received from the August 2019 notice, FDA is adding 18 of the 19 proposed constituents to the HPHC list. Although FDA proposed that ethyl acetoacetate be added to the list, based on it having been tentatively identified as a respiratory toxicant, FDA has determined that there is insufficient information to warrant its inclusion on the list at this time. FDA's determination is based on the fact that ethyl acetoacetate does not meet any of the criteria for adding constituents to the HPHC list, including that NIOSH has not identified it as having adverse respiratory effects. This determination may be revised, consistent with the directive in section 904(e) of the FD&C Act that FDA periodically revise the established list as appropriate. The list of the constituents added to the established HPHC list is in Table 1. ]

| Constituent | Carcinogen (CA), respiratory toxicant (RT), reproductive or developmental
toxicant (RDT), poisonous chemical (PC) |
| --- | --- |
| Acetic Acid | RT |
| Acetoin (also known as 3-hydroxy-2-butanone) | RT |
| Acetyl Propionyl (also known as 2,3-pentanedione) | RT |
| Benzyl Acetate | RT |
| Butyraldehyde | RT |
| Diacetyl | RT |
| Diethylene Glycol | PC |
| ( printed page 21827) | |
| Ethyl Acetate | RT |
| Ethylene Glycol | RT, RDT |
| Furfural | RT |
| Glycerol | RT |
| Glycidol | CA |
| Isoamyl Acetate | RT |
| Isobutyl Acetate | RT |
| Methyl Acetate | RT |
| n-Butanol | RT |
| Propionic Acid | RT |
| Propylene Glycol | RT |

III. Request for Comments and Information

Based on the August 2019 notice, FDA received several comments that suggested adding constituents to the established HPHC list beyond those proposed in the notice. FDA has statutory authority under section 904(e) of the FD&C Act and intends to continue to revise the established HPHC list as additional criteria are defined and additional scientific information becomes available. As a result of comments to the August 2019 notice, FDA is proposing to add three additional constituents to the established list and requests comments on the three proposed additions: pulegone, furfuryl alcohol, and methyl eugenol. These constituents are often added to e-liquid formulations as flavors, but may also be present in other tobacco products, such as cigarettes and smokeless tobacco. FDA has tentatively concluded that these three constituents meet the criteria used in determining whether a constituent is harmful or potentially harmful and should be included on the HPHC established list, unless other scientific information obtained by or submitted to the Agency shows that the constituent is not, in fact, harmful or potentially harmful.

IV. Identification of HPHCs Is an Ongoing Effort

FDA continues to review relevant science to determine whether to add additional constituents to the list. That a constituent has not been so identified by FDA or other entities could be because it does not currently meet established criteria, it has not been adequately studied, or it has not yet been systematically reviewed. Consistent with the obligations under section 904(e) of the FD&C Act, FDA intends to continue: (1) our efforts to review other disease outcomes to assess whether additional chemicals or chemical compounds in tobacco products or tobacco smoke, including chemicals or chemical compounds in the emissions from the range of tobacco products now deemed to be subject to chapter IX of the FD&C Act, are harmful or potentially harmful constituents that contribute to the risk of other diseases; (2) our consideration of whether additional or different criteria should be selected to help identify other classes of harmful or potentially harmful chemicals and chemical compounds for inclusion on the HPHC established list and whether individual constituents should be added; and (3) our efforts to review new information to determine if it would be appropriate to remove one or more of the constituents that appear on the HPHC established list, or to add additional constituents to the list.

| Constituent | Carcinogen (CA), respiratory toxicant (RT), cardiovascular toxicant (CT),
reproductive or developmental toxicant (RDT), addictive (AD), poisonous
chemical (PC), banned in food
(in smokeless tobacco products) |
| --- | --- |
| Acetaldehyde | CA, RT, AD |
| Acetamide | CA |
| Acetic Acid | RT |
| Acetone | RT |
| Acrolein | RT, CT |
| Acrylamide | CA |
| Acrylonitrile | CA, RT |
| Aflatoxin B1 | CA |
| 4-Aminobiphenyl | CA |
| 1-Aminonaphthalene | CA |
| 2-Aminonaphthalene | CA |
| Ammonia | RT |
| Anabasine | AD |
| o-Anisidine | CA |
| Arsenic | CA, CT, RDT |
| ( printed page 21828) | |
| A-α-C (2-Amino-9 H -pyrido[2,3- b ]indole) | CA |
| Benz[a ]anthracene | CA, CT |
| Benz[j ]aceanthrylene | CA |
| Benzene | CA, CT, RDT |
| Benzo[b ]fluoranthene | CA, CT |
| Benzo[k ]fluoranthene | CA, CT |
| Benzo[b ]furan | CA |
| Benzo[a ]pyrene | CA |
| Benzo[c ]phenanthrene | CA |
| Benzyl Acetate | RT |
| Beryllium | CA |
| 1,3-Butadiene | CA, RT, RDT |
| Butyraldehyde | RT |
| Cadmium | CA, RT, RDT |
| Caffeic acid | CA |
| Carbon monoxide | RDT |
| Catechol | CA |
| Chlorinated dioxins/furans | CA, RDT |
| Chromium | CA, RT, RDT |
| Chrysene | CA, CT |
| Cobalt | CA, CT |
| Coumarin | Banned in food |
| Cresols (o-, m-, and p-cresol) | CA, RT |
| Crotonaldehyde | CA |
| Cyclopenta[c,d ]pyrene | CA |
| Diacetyl | RT |
| Dibenz[a,h ]anthracene | CA |
| Dibenzo[a,e ]pyrene | CA |
| Dibenzo[a,h ]pyrene | CA |
| Dibenzo[a,i ]pyrene | CA |
| Dibenzo[a,l ]pyrene | CA |
| Diethylene Glycol | PC |
| 2,6-Dimethylaniline | CA |
| Ethyl Acetate | RT |
| Ethyl carbamate (urethane) | CA, RDT |
| Ethylbenzene | CA |
| Ethylene Glycol | RT, RDT |
| Ethylene oxide | CA, RT, RDT |
| Formaldehyde | CA, RT |
| Furan | CA |
| Furfural | RT |
| Glu-P-1 (2-Amino-6-methyldipyrido[1,2- a: 3′,2′- d ]imidazole) | CA |
| Glu-P-2 (2-Aminodipyrido[1,2- a: 3′,2′- d ]imidazole) | CA |
| Glycerol | RT |
| Glycidol | CA |
| Hydrazine | CA, RT |
| Hydrogen cyanide | RT, CT |
| Indeno[1,2,3-cd ]pyrene | CA |
| IQ (2-Amino-3-methylimidazo[4,5- f ]quinoline) | CA |
| Isoamyl Acetate | RT |
| Isobutyl Acetate | RT |
| Isoprene | CA |
| Lead | CA, CT, RDT |
| MeA-α-C (2-Amino-3-methyl)-9 H -pyrido[2,3- b ]indole) | CA |
| Mercury | CA, RDT |
| Methyl Acetate | RT |
| Methyl Ethyl Ketone | RT |
| 5-Methylchrysene | CA |
| 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) | CA |
| Naphthalene | CA, RT |
| n-Butanol | RT |
| Nickel | CA, RT |
| Nicotine | RDT, AD |
| Nitrobenzene | CA, RT, RDT |
| Nitromethane | CA |
| 2-Nitropropane | CA |
| ( printed page 21829) | |
| N -Nitrosodiethanolamine (NDELA) | CA |
| N -Nitrosodiethylamine | CA |
| N -Nitrosodimethylamine (NDMA) | CA |
| N -Nitrosomethylethylamine | CA |
| N -Nitrosomorpholine (NMOR) | CA |
| N -Nitrosonornicotine (NNN) | CA |
| N -Nitrosopiperidine (NPIP) | CA |
| N -Nitrosopyrrolidine (NPYR) | CA |
| N -Nitrososarcosine (NSAR) | CA |
| Nornicotine | AD |
| Phenol | RT, CT |
| PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5- b ]pyridine) | CA |
| Polonium-210 | CA |
| Propionic Acid | RT |
| Propionaldehyde | RT, CT |
| Propylene Glycol | RT |
| Propylene oxide | CA, RT |
| Quinoline | CA |
| Selenium | RT |
| Styrene | CA |
| o-Toluidine | CA |
| Toluene | RT, RDT |
| Trp-P-1 (3-Amino-1,4-dimethyl-5 H -pyrido[4,3- b ]indole) | CA |
| Trp-P-2 (1-Methyl-3-amino-5 H -pyrido[4,3- b ]indole ) | CA |
| Uranium-235 | CA, RT |
| Uranium-238 | CA, RT |
| Vinyl acetate | CA, RT |
| Vinyl chloride | CA |
Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

Footnotes

1.

 
See
“Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act,” 81 FR 28974 (May 10, 2016), codified at 21 CFR part 1100. On August 9, 2023, the U.S. District Court for the District of Columbia issued an order vacating FDA's rule deeming tobacco products to be subject to FDA's tobacco product authorities “insofar as it applies to premium cigars.” Cigar Ass'n of Am. v. FDA, No. 16-cv-01460, 2023 WL 5094869, at *6 (D.D.C. Aug. 9, 2023), affirmed in part, reversed in part, and remanded, 132 F.4th 535 (D.C. Cir. 2025).

2.

 FDA revised the 2011 Guidance that discusses the meaning of HPHC in the context of the HPHC list requirement in August 2016. “Harmful and Potentially Harmful Constituents” in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act available at https://www.fda.gov/​media/​80109/​download.

3.

 “Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List,” 77 FR 20034 (April 3, 2012).

4.

 “Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List,” 77 FR 20034 (April 3, 2012).

5.

 “Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Request for Comments,” 76 FR 50226 (August 12, 2011).

6.

 See Appendix A for complete HPHC established list.

[FR Doc. 2026-07910 Filed 4-22-26; 8:45 am]

BILLING CODE 4164-01-P

Published Document: 2026-07910 (91 FR 21824)